<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NIZORAL- ketoconazole tablet </strong><br>Janssen Pharmaceuticals, Inc.<br></p></div>
<h1>NIZORAL<span class="Sup">®</span><br>(KETOCONAZOLE)<br>TABLETS</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING</span></h1>
<p class="First">NIZORAL<span class="Sup">®</span> Tablets should be used only when other effective antifungal therapy is not available or tolerated and the potential benefits are considered to outweigh the potential risks.</p>
<p><span class="Bold">Hepatotoxicity</span></p>
<p>Serious hepatotoxicity, including cases with a fatal outcome or requiring liver transplantation has occurred with the use of oral ketoconazole. Some patients had no obvious risk factors for liver disease. Patients receiving this drug should be informed by the physician of the risk and should be closely monitored. See <a href="#WARNINGS"> WARNINGS </a> section.</p>
<p><span class="Bold">QT Prolongation and Drug Interactions Leading to QT Prolongation</span></p>
<p>Co-administration of the following drugs with ketoconazole is contraindicated: dofetilide, quinidine, pimozide, cisapride, methadone, disopyramide, dronedarone, ranolazine. Ketoconazole can cause elevated plasma concentrations of these drugs and may prolong QT intervals, sometimes resulting in life-threatening ventricular <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span> such as <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>. See <a href="#contraindications">CONTRAINDICATIONS</a>, <a href="#warnings">WARNINGS</a>, and <a href="#prec_di"> PRECAUTIONS: Drug Interactions </a> sections.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="description"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">NIZORAL<span class="Sup">® </span>is a synthetic broad-spectrum antifungal agent available in scored white tablets, each containing 200 mg ketoconazole base for oral administration. Inactive ingredients are colloidal silicon dioxide, corn starch, lactose, magnesium stearate, microcrystalline cellulose, and povidone. Ketoconazole is <span class="Underline">cis</span>-1- acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxyl]phenyl] piperazine and has the following structural formula:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=090660c1-6e6d-457f-adb5-046ddfcd1465&amp;name=nizoral-01.jpg"></div>
<p>Ketoconazole is a white to slightly beige, odorless powder, soluble in acids, with a molecular weight of 531.44.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="clinical_pharmacology"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43682-4">
<a name="pharmacokinetics"></a><a name="section-2.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.1"></a><p></p>
<h3>Absorption</h3>
<p class="First">Ketoconazole is a weak dibasic agent and thus requires acidity for dissolution and absorption.</p>
<p>Mean peak plasma concentrations of approximately 3.5 µg/mL are reached within 1 to 2 hours, following oral administration of a single 200 mg dose taken with a meal. Oral bioavailability is maximal when the tablets are taken with a meal.</p>
<p>Absorption of NIZORAL<span class="Sup">®</span> Tablets is reduced in subjects with reduced gastric acidity, such as subjects taking medications known as acid neutralizing medicines (e.g. aluminum hydroxide) and gastric acid secretion suppressors (e.g. H<span class="Sub">2</span>-receptor antagonists, proton pump inhibitors) or subjects with <span class="product-label-link" type="condition" conceptid="193804" conceptname="Achlorhydria">achlorhydria</span> caused by certain diseases. (See Section <a href="#prec_di">PRECAUTIONS: Drug Interactions</a>.) Absorption of ketoconazole under fasted conditions in these subjects is increased when NIZORAL<span class="Sup">®</span> Tablets are administered with an acidic beverage (such as non-diet cola). After pretreatment with omeprazole, a proton pump inhibitor, the bioavailability of a single 200-mg dose of ketoconazole under fasted conditions was decreased to 17% of the bioavailability of ketoconazole administered alone. When ketoconazole was administered with non-diet cola after pretreatment with omeprazole, the bioavailability was 65% of that after administration of ketoconazole alone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.2"></a><p></p>
<h3>Distribution</h3>
<p class="First"><span class="Italics">In vitro</span>, the plasma protein binding is about 99% mainly to the albumin fraction. Ketoconazole is widely distributed into tissues; however, only a negligible proportion reaches the cerebrospinal fluid.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.3"></a><p></p>
<h3>Metabolism</h3>
<p class="First">Following absorption from the gastrointestinal tract, NIZORAL<span class="Sup">® </span> is converted into several inactive metabolites. <span class="Italics">In vitro</span> studies have shown that CYP3A4 is the major enzyme involved in the metabolism of ketoconazole. The major identified metabolic pathways are oxidation and degradation of the imidazole and piperazine rings, by hepatic microsomal enzymes. In addition,  oxidative O-dealkylation and aromatic hydroxylation does occur. Ketoconazole has not been demonstrated to induce its own metabolism.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.4"></a><p></p>
<h3>Elimination</h3>
<p class="First">Elimination from plasma is biphasic with a half-life of 2 hours during the first 10 hours and 8 hours thereafter.</p>
<p>Approximately 13% of the dose is excreted in the urine, of which 2 to 4% is unchanged drug. The major route of excretion is through the bile into the intestinal tract with about 57% being excreted in the feces.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.5"></a><p></p>
<h3>Special Populations</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.5.1"></a><p></p>
<h4>Patients with Hepatic or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h4>
<p class="First">In patients with hepatic or <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the overall pharmacokinetics of ketoconazole was not significantly different when compared with healthy subjects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.5.2"></a><p></p>
<h4>Pediatric Patients</h4>
<p class="First">Limited pharmacokinetic data are available on the use of NIZORAL<span class="Sup">® </span> Tablets in the pediatric population.</p>
<p>Measurable ketoconazole plasma concentrations have been observed in pre-term infants (single or daily doses of 3 to 10 mg/kg) and in pediatric patients 5 months of age and older (daily doses of 3 to 13 mg/kg) when the drug was administered as a suspension, tablet or crushed tablet. Limited data suggest that absorption may be greater when the drug is administered as a suspension compared to a crushed tablet. Conditions that raise gastric pH may lower or prevent absorption (See Section <a href="#prec_di">PRECAUTIONS: Drug Interactions</a>). Maximum plasma concentrations occurred 1 to 2 hours after dosing and were in the same general range as those seen in adults who received a 200–400 mg dose.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.2"></a><p></p>
<h2>Electrocardiogram</h2>
<p class="First">Pre-clinical electrophysiological studies have shown that ketoconazole inhibits the rapidly activating component of the cardiac delayed rectifier potassium current, prolongs the action potential duration, and may prolong the QT<span class="Sub">c</span> interval. Data from some clinical PK/PD studies and drug interaction studies suggest that oral dosing with ketoconazole at 200 mg twice daily for 3–7 days can result in an increase of the QT<span class="Sub">c</span> interval: a mean maximum increase of about 6 to 12 msec was seen at ketoconazole peak plasma concentrations about 1–4 hours after ketoconazole administration.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="section-2.3"></a><p></p>
<h2>MICROBIOLOGY</h2>
<div class="Section" data-sectionCode="43679-0">
<a name="section-2.3.1"></a><p></p>
<h3>Mechanism of Action</h3>
<p class="First">Ketoconazole blocks the synthesis of ergosterol, a key component of the fungal cell membrane, through the inhibition of cytochrome P-450 dependent enzyme lanosterol 14α-demethylase responsible for the conversion of lanosterol to ergosterol in the fungal cell membrane. This results in an accumulation of methylated sterol precursors and a depletion of ergosterol within the cell membrane thus weakening the structure and function of the fungal cell membrane.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.3.2"></a><p></p>
<h3>Activity In Vitro &amp; In Vivo</h3>
<p class="First">NIZORAL<span class="Sup">® </span> Tablets are active against clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> with <span class="Italics">Blastomyces dermatitidis</span>, <span class="Italics">Coccidioides immitis</span>, <span class="Italics">Histoplasma capsulatum</span>, <span class="Italics">Paracoccidioides brasiliensis</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">NIZORAL<span class="Sup">® </span> Tablets should be used only when other effective antifungal therapy is not available or tolerated and the potential benefits are considered to outweigh the potential risks.</p>
<p>NIZORAL<span class="Sup">® </span> (ketoconazole) Tablets are indicated for the treatment of the following systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> in patients who have failed or who are intolerant to other therapies: <span class="product-label-link" type="condition" conceptid="433146" conceptname="Blastomycosis">blastomycosis</span>, <span class="product-label-link" type="condition" conceptid="437217" conceptname="Coccidioidomycosis">coccidioidomycosis</span>, <span class="product-label-link" type="condition" conceptid="433134" conceptname="Histoplasmosis">histoplasmosis</span>, chromomycosis, and paracoccidioidomycosis. NIZORAL<span class="Sup">® </span> Tablets should not be used for fungal <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> because it penetrates poorly into the cerebrospinal fluid.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="contraindications"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="34073-7">
<a name="section-4.1"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Coadministration of a number of CYP3A4 substrates such as dofetilide, quinidine cisapride and pimozide is contraindicated with NIZORAL<span class="Sup">® </span> Tablets. Coadministration with ketoconazole can cause elevated plasma concentrations of these drugs and may increase or prolong both therapeutic and adverse effects to such an extent that a potentially serious adverse reaction may occur. For example, increased plasma concentrations of some of these drugs can lead to QT prolongation and sometimes resulting in life-threatening <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachyarrhythmias</span> including occurrences of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>, a potentially fatal <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>. (See <a href="#prec_di">PRECAUTIONS: Drug Interactions</a>.)</p>
<p>Additionally, the following other drugs are contraindicated with NIZORAL<span class="Sup">® </span> Tablets: methadone, disopyramide, dronedarone, ergot alkaloids such as dihydroergotamine, ergometrine, ergotamine, methylergometrine, irinotecan, lurasidone, oral midazolam,  alprazolam, triazolam, felodipine, nisoldipine, ranolazine, tolvaptan, eplerenone, lovastatin, simvastatin and colchicine. (See <a href="#prec_di">PRECAUTIONS: Drug Interactions</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.2"></a><p></p>
<h2>Enhanced Sedation</h2>
<p class="First">Coadministration of NIZORAL<span class="Sup">® </span> Tablets with oral midazolam, oral triazolam or alprazolam has resulted in elevated plasma concentrations of these drugs. This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents. Concomitant administration of NIZORAL<span class="Sup">® </span> Tablets with oral triazolam, oral midazolam or alprazolam is contraindicated. (See <a href="#prec_di">PRECAUTIONS: Drug Interactions</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">Myopathy</span></h2>
<p class="First">Coadministration of CYP3A4 metabolized HMG-CoA reductase inhibitors such as simvastatin, and lovastatin is contraindicated with NIZORAL<span class="Sup">® </span> Tablets. (See <a href="#prec_di">PRECAUTIONS: Drug Interactions</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">Ergotism</span></h2>
<p class="First">Concomitant administration of ergot alkaloids such as dihydroergotamine and ergotamine with NIZORAL<span class="Sup">® </span> Tablets is contraindicated. (See <a href="#prec_di">PRECAUTIONS: Drug Interactions</a>.)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.5"></a><p></p>
<h2>Liver Disease</h2>
<p class="First">The use of NIZORAL<span class="Sup">® </span> Tablets is contraindicated in patients with acute or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.6"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First">NIZORAL<span class="Sup">® </span> is contraindicated in patients who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug.</p>
</div>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warnings"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">NIZORAL<span class="Sup">® </span> Tablets should be used only when other effective antifungal therapy is not available or tolerated and the potential benefits are considered to outweigh the potential risks.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.1"></a><p></p>
<h2>Hepatotoxicity</h2>
<p class="First">Serious hepatotoxicity, including cases with a fatal outcome or requiring liver transplantation, has occurred with the use of oral ketoconazole. Some patients had no obvious risk factors for liver disease. Serious hepatotoxicity was reported both by patients receiving high doses for short treatment durations and by patients receiving low doses for long durations.</p>
<p>The hepatic injury has usually, but not always, been reversible upon discontinuation of NIZORAL<span class="Sup">® </span> Tablets treatment. Cases of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> have been reported in children.</p>
<p>At baseline, obtain laboratory tests (such as SGGT, alkaline phosphatase, ALT, AST, total bilirubin (TBL), <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> Time (PT), International Normalization Ratio (INR), and testing for viral hepatitides). Patients should be advised against alcohol consumption while on treatment. If possible, use of other potentially hepatotoxic drugs should be avoided in patients receiving NIZORAL<span class="Sup">® </span> Tablets.</p>
<p>Prompt recognition of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> is essential. During the course of treatment, serum ALT should be monitored weekly for the duration of treatment. If ALT values increase to a level above the upper limit of normal or 30 percent above baseline, or if the patient develops symptoms, ketoconazole treatment should be interrupted and a full set of liver tests should be obtained. Liver tests should be repeated to ensure normalization of values. Hepatotoxicity has been reported with restarting oral ketoconazole (rechallenge). If it is decided to restart oral ketoconazole, monitor the patient frequently to detect any recurring <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> from the drug.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.2"></a><p></p>
<h2>QT Prolongation and Drug Interactions Leading to QT Prolongation</h2>
<p class="First">Ketoconazole can prolong the QT interval. Co-administration of the following drugs with ketoconazole is contraindicated: dofetilide, quinidine, pimozide, cisapride, methadone, disopyramide, dronedarone, ranolazine. Ketoconazole can cause elevated plasma concentrations of these drugs which may prolong the QT interval, sometimes resulting in life-threatening ventricular <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span> such as <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsades de pointes</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">Adrenal Insufficiency</span></h2>
<p class="First">NIZORAL<span class="Sup">® </span> Tablets decrease adrenal corticosteroid secretion at doses of 400 mg and higher. This effect is not shared with other azoles. The recommended dose of 200 mg – 400 mg daily should not be exceeded.</p>
<p>Adrenal function should be monitored in patients with <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> or with borderline adrenal function and in patients under <span class="product-label-link" type="condition" conceptid="4088438" conceptname="Prolonged periods">prolonged periods</span> of stress (major surgery, intensive care, etc.).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.4"></a><p></p>
<h2>Adverse Reactions Associated with Unapproved Uses</h2>
<p class="First">Ketoconazole has been used in high doses for the treatment of advanced prostate cancer and for Cushing's syndrome when other treatment options have failed. The safety and effectiveness of ketoconazole have not been established in these settings and the use of ketoconazole for these indications is not approved by FDA.</p>
<p>In a clinical trial involving 350 patients with metastatic prostatic cancer, eleven <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were reported within two weeks of starting treatment with high doses of ketoconazole tablets (1200 mg/day). It is not possible to ascertain from the information available whether <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was related to ketoconazole therapy or <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> in these patients with serious underlying disease.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> has been reported after the first dose. Several cases of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> including <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> have also been reported.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="precautions"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="prec_general"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">NIZORAL<span class="Sup">® </span> Tablets have been demonstrated to lower serum testosterone. Once therapy with NIZORAL<span class="Sup">® </span> Tablets has been discontinued, serum testosterone levels return to baseline values. Testosterone levels are impaired with doses of 800 mg per day and abolished by 1600 mg per day. Clinical manifestations of decreased testosterone concentrations may include <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> and <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">oligospermia</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="prec_ifp"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be instructed to report any signs and symptoms which may suggest liver dysfunction so that appropriate biochemical testing can be done. Such signs and symptoms may include unusual <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, dark urine or <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> stools (see <a href="#warnings"> WARNINGS </a> section).</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="prec_di"></a><a name="section-6.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Ketoconazole is mainly metabolized through CYP3A4. Other substances that either share this metabolic pathway or modify CYP3A4 activity may influence the pharmacokinetics of ketoconazole. Similarly, ketoconazole may modify the pharmacokinetics of other substances that share this metabolic pathway. Ketoconazole is a potent CYP3A4 inhibitor and a P-glycoprotein inhibitor. When using concomitant medication, the corresponding label should be consulted for information on the route of metabolism and the possible need to adjust dosages.</p>
<p>Interaction studies have only been performed in adults. The relevance of the results from these studies in pediatric patients is unknown.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="decrease"></a><a name="section-6.3.1"></a><p></p>
<h3>Drugs that may decrease ketoconazole plasma concentrations</h3>
<p class="First">Drugs that reduce the gastric acidity (e.g. acid neutralizing medicines such as aluminum hydroxide, or acid secretion suppressors such as H<span class="Sub">2</span>-receptor antagonists and proton pump inhibitors) impair the absorption of ketoconazole from NIZORAL<span class="Sup">® </span> Tablets. These drugs should be used with caution when coadministered with NIZORAL<span class="Sup">® </span> Tablets:</p>
<ul>
<li>NIZORAL<span class="Sup">® </span> Tablets should be administered with an acidic beverage (such as non-diet cola) upon co-treatment with drugs reducing gastric acidity.</li>
<li>Acid neutralizing medicines (e.g. aluminum hydroxide) should be administered at least 1 hour before or 2 hours after the intake of NIZORAL<span class="Sup">® </span> Tablets.</li>
<li>Upon coadministration, the antifungal activity should be monitored and the NIZORAL<span class="Sup">® </span> Tablets dose increased as deemed necessary.</li>
</ul>
<p>Coadministration of NIZORAL<span class="Sup">® </span> Tablets with potent enzyme inducers of CYP3A4 may decrease the bioavailability of ketoconazole to such an extent that efficacy may be reduced. Examples include:</p>
<ul>
<li>Antibacterials: isoniazid, rifabutin (see also under '<a href="#drugs_with_plasma_concentrations_increased">Drugs that may have their plasma concentrations increased</a>'), rifampicin.</li>
<li>Anticonvulsants: carbamazepine (see also under '<a href="#drugs_with_plasma_concentrations_increased">Drugs that may have their plasma concentrations increased</a>'), phenytoin.</li>
<li>Antivirals: efavirenz, nevirapine.</li>
</ul>
<p>Therefore, administration of potent enzyme inducers of CYP3A4 with NIZORAL<span class="Sup">® </span> Tablets is not recommended. The use of these drugs should be avoided from 2 weeks before and during treatment with NIZORAL<span class="Sup">® </span> Tablets, unless the benefits outweigh the risk of potentially reduced ketoconazole efficacy. Upon coadministration, the antifungal activity should be monitored and the NIZORAL<span class="Sup">® </span> Tablets dose increased as deemed necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3.2"></a><p></p>
<h3>Drugs that may increase ketoconazole plasma concentrations</h3>
<p class="First">Potent inhibitors of CYP3A4 (e.g. antivirals such as ritonavir, ritonavir-boosted darunavir and ritonavir-boosted fosamprenavir) may increase the bioavailability of ketoconazole. These drugs should be used with caution when coadministered with NIZORAL<span class="Sup">® </span> Tablets. Patients who must take NIZORAL<span class="Sup">® </span> Tablets concomitantly with potent inhibitors of CYP3A4 should be monitored closely for signs or symptoms of increased or prolonged pharmacologic effects of ketoconazole, and the NIZORAL<span class="Sup">® </span> Tablets dose should be decreased as deemed necessary. When appropriate, ketoconazole plasma concentrations should be measured.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="drugs_with_plasma_concentrations_increased"></a><a name="section-6.3.3"></a><p></p>
<h3>Drugs that may have their plasma concentrations increased by ketoconazole</h3>
<p class="First">Ketoconazole can inhibit the metabolism of drugs metabolized by CYP3A4 and can inhibit the drug transport by P-glycoprotein, which may result in increased plasma concentrations of these drugs and/or their active metabolite(s) when they are administered with ketoconazole. These elevated plasma concentrations may increase or prolong both therapeutic and adverse effects of these drugs. CYP3A4-metabolized drugs known to prolong the QT interval may be contraindicated with NIZORAL<span class="Sup">®</span> Tablets, since the combination may lead to <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachyarrhythmias</span>, including occurrences of <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>, a potentially fatal <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>.</p>
<p>Examples of drugs that may have their plasma concentrations increased by ketoconazole presented by drug class with advice regarding coadministration with NIZORAL<span class="Sup">®</span> Tablets:</p>
<table width="100%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Drug Class</th>
<th class="Rrule" align="left">Contraindicated</th>
<th class="Rrule" align="left">Not Recommended</th>
<th class="Rrule" align="left">Use with Caution</th>
<th class="Rrule" align="left">Comments</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"></td>
<td class="Rrule" align="left"><span class="Italics">Under no circumstances should the drug be coadministered with NIZORAL<span class="Sup">® </span> Tablets, and up to one week after discontinuation of treatment with ketoconazole.</span></td>
<td class="Rrule" align="left"><span class="Italics">The use of the drug should be avoided during and up to one week after discontinuation of treatment with NIZORAL<span class="Sup">® </span> Tablets, unless the benefits outweigh the potentially increased risks of side effects. If coadministration cannot be avoided, clinical monitoring for signs or symptoms of increased or prolonged effects or side effects of the interacting drug is recommended, and its dosage should be reduced or interrupted as deemed necessary. When appropriate, plasma concentrations should be measured. The label of the coadministered drug should be consulted for information on dose adjustment and adverse effects.</span></td>
<td class="Rrule" align="left"><span class="Italics">Careful monitoring is recommended when the drug is coadministered with NIZORAL<span class="Sup">® </span> Tablets. Upon coadministration, patients should be monitored closely for signs or symptoms of increased or prolonged effects or side effects of the interacting drug, and its dosage should be reduced as deemed necessary. When appropriate, plasma concentrations should be measured. The label of the coadministered drug should be consulted for information on dose adjustment and adverse effects.</span></td>
<td class="Rrule" align="left"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Alpha Blockers</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">tamsulosin</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Analgesics</td>
<td class="Rrule" align="left">methadone</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">alfentanil, buprenorphine IV and sublingual, fentanyl, oxycodone, sufentanil</td>
<td class="Rrule" align="left">
<p class="First">Methadone: The potential increase in plasma concentrations of methadone when coadministered with NIZORAL<span class="Sup">® </span> Tablets may increase the risk of serious cardiovascular events including QT prolongation and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>, or respiratory or <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>. [See <a href="#contraindications">CONTRAINDICATIONS</a>.]</p>
<br><p>Fentanyl: The potential increase in plasma concentrations of fentanyl when coadministered with NIZORAL<span class="Sup">® </span> Tablets may increase the risk of potentially fatal <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</p>
<br><p>Sufentanil: No human pharmacokinetic data of an interaction with ketoconazole are available. <span class="Italics"> In vitro </span> data suggest that sufentanil is metabolized by CYP3A4 and so potentially increased sufentanil plasma concentrations would be expected when coadministered with NIZORAL<span class="Sup">® </span> Tablets.</p>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antiarrhythmics</td>
<td class="Rrule" align="left">disopyramide, dofetilide, dronedarone, quinidine</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">digoxin</td>
<td class="Rrule" align="left">
<p class="First">Disopyramide, dofetilide, dronedarone, quinidine: The potential increase in plasma concentrations of these drugs when coadministered with ketoconazole may increase the risk of serious cardiovascular events including QT prolongation.</p>
<br><p>Digoxin: Rare cases of elevated plasma concentrations of digoxin have been reported. It is not clear whether this was due to the combination of therapy. It is, therefore, advisable to monitor digoxin concentrations in patients receiving ketoconazole.</p>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antibacterials</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">rifabutin</td>
<td class="Rrule" align="left">telithromycin</td>
<td class="Rrule" align="left">
<p class="First">Rifabutin: see also under '<a href="#decrease">Drugs that may decrease ketoconazole plasma concentrations</a>'.</p>
<br><p>Telithromycin: A multiple-dose interaction study with ketoconazole showed that C<span class="Sub">max</span> of telithromycin was increased by 51% and AUC by 95%.</p>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Anticoagulants and Antiplatelet Drugs</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">rivaroxaban</td>
<td class="Rrule" align="left">cilostazol, coumarins, dabigatran</td>
<td class="Rrule" align="left">
<p class="First">Cilostazol: Concomitant administration of single doses of cilostazol 100 mg and ketoconazole 400 mg approximately doubled cilostazol concentrations and altered (increase/decrease) the concentrations of the active metabolites of cilostazol.</p>
<br><p>Coumarins: Ketoconazole may enhance the anticoagulant effect of coumarin-like drugs, thus the anticoagulant effect should be carefully titrated and monitored.</p>
<br><p>Dabigatran: In patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCL 50 mL/min to ≤ 80 mL/min), consider reducing the dose of dabigatran to 75 mg twice daily when it is coadministered with ketoconazole.</p>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Anticonvulsants</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">carbamazepine</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">Carbamazepine: <span class="Italics"> In vivo </span> studies have demonstrated an increase in plasma carbamazepine concentrations in subjects concomitantly receiving ketoconazole. In addition, the bioavailability of ketoconazole may be reduced by carbamazepine.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antidiabetics</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">repaglinide, saxagliptin</td>
<td class="Rrule" align="left"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antihelmintics and Antiprotozoals</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">praziquantel</td>
<td class="Rrule" align="left"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antimigraine Drugs</td>
<td class="Rrule" align="left">ergot alkaloids, such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">eletriptan</td>
<td class="Rrule" align="left">
<p class="First">Ergot alkaloids: The potential increase in plasma concentrations of ergot alkaloids when coadministered with NIZORAL<span class="Sup">® </span> Tablets may increase the risk of <span class="product-label-link" type="condition" conceptid="4201303" conceptname="Ergotism">ergotism</span>, i.e., a risk for <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> potentially leading to <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the extremities.</p>
<br><p>Eletriptan: Eletriptan should be used with caution with ketoconazole, and specifically, should not be used within at least 72 hours of treatment with ketoconazole.</p>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antineoplastics</td>
<td class="Rrule" align="left">irinotecan</td>
<td class="Rrule" align="left">dasatinib, lapatinib, nilotinib</td>
<td class="Rrule" align="left">bortezomib, busulphan, docetaxel, erlotinib, imatinib, ixabepilone, paclitaxel, trimetrexate, vinca alkaloids</td>
<td class="Rrule" align="left">
<p class="First">Irinotecan: The potential increase in plasma concentrations of irinotecan when coadministered with NIZORAL<span class="Sup">® </span> Tablets may increase the risk of potentially fatal adverse events.</p>
<br><p>Docetaxel: In the presence of ketoconazole, the clearance of docetaxel in cancer patients was shown to decrease by 50%.</p>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antipsychotics, Anxiolytics and Hypnotics</td>
<td class="Rrule" align="left">alprazolam, lurasidone, oral midazolam, pimozide, triazolam</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">aripiprazole, buspirone, haloperidol, midazolam IV, quetiapine, ramelteon, risperidone</td>
<td class="Rrule" align="left">
<p class="First">Alprazolam, midazolam, triazolam: Coadministration of NIZORAL<span class="Sup">® </span> Tablets with oral midazolam or triazolam, or alprazolam may cause several-fold increases in plasma concentrations of these drugs. This may potentiate and prolong hypnotic and sedative effects, especially with repeated dosing or chronic administration of these agents.</p>
<br><p>Pimozide: The potential increase in plasma concentrations of pimozide when coadministered with NIZORAL<span class="Sup">® </span> Tablets may increase the risk of serious cardiovascular events including QT prolongation and <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>.</p>
<br><p>Aripiprazole: Coadministration of ketoconazole (200 mg/day for 14 days) with a 15 mg single dose of aripiprazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively. The effect of a higher ketoconazole dose (400 mg/day) has not been studied. When ketoconazole is given concomitantly with aripiprazole, the aripiprazole dose should be reduced to one-half of the recommended dose.</p>
<br><p>Buspirone: Ketoconazole is expected to inhibit buspirone metabolism and increase plasma concentrations of buspirone. If a patient has been titrated to a stable dosage on buspirone, a dose reduction of buspirone may be necessary to avoid adverse events attributable to buspirone or diminished anxiolytic activity.</p>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Antivirals</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">indinavir, maraviroc, saquinavir</td>
<td class="Rrule" align="left"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Beta Blockers</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">nadolol</td>
<td class="Rrule" align="left"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Calcium Channel Blockers</td>
<td class="Rrule" align="left">felodipine, nisoldipine</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">other dihydropyridines, verapamil</td>
<td class="Rrule" align="left">
<p class="First">Calcium channel blockers can have a negative inotropic effect which may be additive to those of ketoconazole. The potential increase in plasma concentrations of calcium channel blockers when co-administered with NIZORAL<span class="Sup">® </span> Tablets may increase the risk of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.</p>
<br><p>Dihydropyridines: Concomitant administration of NIZORAL<span class="Sup">® </span> Tablets may cause several-fold increases in plasma concentrations of dihydropyridines.</p>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Cardiovascular Drugs, Miscellaneous</td>
<td class="Rrule" align="left">ranolazine</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">aliskiren, bosentan</td>
<td class="Rrule" align="left">
<p class="First">Ranolazine: The potential increase in plasma concentrations of ranolazine when coadministered with NIZORAL<span class="Sup">® </span> Tablets may increase the risk of serious cardiovascular events including QT prolongation.</p>
<br><p>Bosentan: Coadministration of bosentan 125 mg twice daily and ketoconazole, increased the plasma concentrations of bosentan by approximately 2-fold in normal volunteers. No dose adjustment of bosentan is necessary, but patients should be monitored for increased pharmacologic effects and adverse reactions of bosentan.</p>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Diuretics</td>
<td class="Rrule" align="left">eplerenone</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">The potential increase in plasma concentrations of eplerenone when coadministered with NIZORAL<span class="Sup">® </span> Tablets may increase the risk of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Gastrointestinal Drugs</td>
<td class="Rrule" align="left">cisapride</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">aprepitant</td>
<td class="Rrule" align="left">Cisapride: Oral ketoconazole potently inhibits the metabolism of cisapride resulting in a mean eight-fold increase in AUC of cisapride, which can lead to serious cardiovascular events including QT prolongation.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Immunosuppressants</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">everolimus, rapamycin (also known as sirolimus), temsirolimus</td>
<td class="Rrule" align="left">budesonide, ciclesonide, cyclosporine, dexamethasone, fluticasone, methylprednisolone, tacrolimus</td>
<td class="Rrule" align="left">
<p class="First">Rapamycin (sirolimus): NIZORAL<span class="Sup">® </span> Tablets 200 mg daily for 10 days increased the C<span class="Sub">max</span> and AUC of a single 5-mg dose of sirolimus by 4.3-fold and 10.9-fold, respectively in 23 healthy subjects.</p>
<br><p>Fluticasone: Coadministration of fluticasone propionate and ketoconazole is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects.</p>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Lipid Regulating Drugs</td>
<td class="Rrule" align="left">lovastatin, simvastatin</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">atorvastatin</td>
<td class="Rrule" align="left">The potential increase in plasma concentrations of atorvastatin, lovastatin and simvastatin when coadministered with NIZORAL<span class="Sup">® </span> Tablets may increase the risk of skeletal muscle toxicity, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>.</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Respiratory Drugs</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">salmeterol</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Urological Drugs</td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left"></td>
<td class="Rrule" align="left">fesoterodine, sildenafil, solifenacin, tadalafil, tolterodine, vardenafil</td>
<td class="Rrule" align="left">Vardenafil: A single dose of 5 mg of vardenafil should not be exceeded when coadministered with ketoconazole.</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left">Other</td>
<td class="Rrule" align="left">colchicine, in subjects with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>; tolvaptan</td>
<td class="Rrule" align="left">colchicine</td>
<td class="Rrule" align="left">alcohol, cinacalcet</td>
<td class="Rrule" align="left">
<p class="First">Colchicine: The potential increase in plasma concentrations of colchicine when coadministered with NIZORAL<span class="Sup">® </span> Tablets may increase the risk of potentially fatal adverse events.</p>
<br><p>Tolvaptan: Ketoconazole 200 mg administered with tolvaptan increased tolvaptan exposure by 5-fold. Larger doses would be expected to produce larger increases in tolvaptan exposure. There is not adequate experience to define the dose adjustment that would be needed to allow safe use of tolvaptan with strong CYP3A inhibitors such as ketoconazole.</p>
<br><p>Alcohol: Exceptional cases have been reported of a disulfiram-like reaction to alcohol, characterized by <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. All symptoms completely resolved within a few hours.</p>
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="prec_cmiof"></a><a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Ketoconazole did not show any signs of mutagenic potential when evaluated using the dominant lethal mutation test or the <span class="Italics"> Ames <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> </span> microsomal activator assay. Ketoconazole was not carcinogenic in an 18-month, oral study in Swiss albino mice or a 24-month oral carcinogenicity study in Wistar rats at dose levels of 5, 20 and 80 mg/kg/day. The high dose in these studies was approximately 1× (mouse) or 2× (rat) the clinical dose in humans based on a mg/m<span class="Sup">2</span> comparison.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="prec_preg"></a><a name="section-6.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="prec_te"></a><a name="section-6.5.1"></a><p></p>
<h3>Teratogenic effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.5.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">Ketoconazole has been shown to be teratogenic (syndactylia and oligodactylia) in the rat when given in the diet at 80 mg/kg/day (2 times the maximum recommended human dose, based on body surface area comparisons). However, these effects may be related to maternal toxicity, evidence of which also was seen at this and higher dose levels.</p>
<p>There are no adequate and well controlled studies in pregnant women. NIZORAL<span class="Sup">® </span> Tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="prec_ne"></a><a name="section-6.5.2"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First">Ketoconazole has also been found to be embryotoxic in the rat when given in the diet at doses higher than 80 mg/kg during the first trimester of gestation.</p>
<p>In addition, dystocia (difficult labor) was noted in rats administered oral ketoconazole during the third trimester of gestation. This occurred when ketoconazole was administered at doses higher than 10 mg/kg (about one fourth the maximum human dose, based on body surface area comparison).</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="prec_nm"></a><a name="section-6.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Ketoconazole has been shown to be excreted in the milk. Mothers who are under treatment with NIZORAL<span class="Sup">® </span> Tablets should not breast feed.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="prec_pu"></a><a name="section-6.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">NIZORAL<span class="Sup">® </span> Tablets have not been systematically studied in children of any age, and essentially no information is available on children under 2 years. NIZORAL<span class="Sup">® </span> Tablets should not be used in pediatric patients unless the potential benefit outweighs the risks.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="AR"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The following adverse reactions were reported in clinical trials:</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span></p>
<p><span class="Italics">Metabolism and Nutrition Disorders:</span> <span class="product-label-link" type="condition" conceptid="4010023" conceptname="Alcohol intolerance">alcohol intolerance</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span></p>
<p><span class="Italics">Psychiatric Disorders:</span> <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span></p>
<p><span class="Italics">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">abdominal pain upper</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, <span class="product-label-link" type="condition" conceptid="4217621" conceptname="Black hairy tongue">tongue discoloration</span></p>
<p><span class="Italics">Hepatobiliary Disorders:</span> <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4326594" conceptname="Abnormal liver function">hepatic function abnormal</span></p>
<p><span class="Italics">Skin and Subcutaneous Tissues Disorders:</span> <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4198562" conceptname="Xeroderma">xeroderma</span></p>
<p><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span></p>
<p><span class="Italics">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">menstrual disorder</span></p>
<p><span class="Italics">General Disorders and Administration Site Conditions:</span> <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flush</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema peripheral</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span></p>
<p><span class="Italics">Investigations:</span> platelet count decreased.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="post-marketing_exp"></a><a name="section-7.1"></a><p></p>
<h2>Post-Marketing Experience</h2>
<p class="First">The following adverse reactions have been identified during postapproval use of NIZORAL<span class="Sup">®</span> Tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>The following adverse reactions were reported during post-marketing experience:</p>
<p><span class="Italics">Blood and Lymphatic System Disorders:</span> <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>: </span>allergic conditions including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine Disorders</span>:</span> adrenocortical insufficiency</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span> reversible <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial pressure increased</span> (e.g. <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilloedema</span>, <span class="product-label-link" type="condition" conceptid="4011769" conceptname="Bulging fontanelle">fontanelle bulging</span> in infants)</p>
<p><span class="Italics">Hepatobiliary Disorders:</span> serious hepatotoxicity including <span class="product-label-link" type="condition" conceptid="4318541" conceptname="Cholestatic hepatitis">hepatitis cholestatic</span>, biopsy-confirmed <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, cirrhosis, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> including cases resulting in transplantation or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></p>
<p><span class="Italics">Skin and Subcutaneous Tissue Disorders:</span> <span class="product-label-link" type="condition" conceptid="45773387" conceptname="Acute generalized exanthematous pustulosis">acute generalized exanthematous pustulosis</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span></p>
<p><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span></p>
<p><span class="Italics">Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>; with doses higher than the recommended therapeutic dose of 200 or 400mg daily, <span class="product-label-link" type="condition" conceptid="76744" conceptname="Azoospermia">azoospermia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">In the event of acute accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, treatment consists of supportive and symptomatic measures. Within the first hour after ingestion, activated charcoal may be administered.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">There should be laboratory as well as clinical documentation of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> prior to starting ketoconazole therapy. The usual duration of therapy for systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is 6 months. Treatment should be continued until active <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span> has subsided.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Adults</h2>
<p class="First">The recommended starting dose of NIZORAL<span class="Sup">®</span> (ketoconazole) Tablets is a single daily administration of 200 mg (one tablet). If clinical responsiveness is insufficient within the expected time, the dose of NIZORAL<span class="Sup">®</span> Tablets may be increased to 400 mg (two tablets) once daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>Children</h2>
<p class="First">In small numbers of children over 2 years of age, a single daily dose of 3.3 to 6.6 mg/kg has been used. NIZORAL<span class="Sup">®</span> Tablets have not been studied in children under 2 years of age.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">NIZORAL<span class="Sup">® </span> (ketoconazole) is available as white, scored tablets containing 200 mg of ketoconazole debossed "JANSSEN" and on the reverse side debossed "NIZORAL". They are supplied in bottles of 100 tablets (NDC 50458-220-10).</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-10.1"></a><p></p>
<p class="First">Store at controlled room temperature 15°–25°C (59°–77°F).</p>
<p>Protect from moisture.</p>
<p>Keep out of reach of children.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<p class="First">Rev. February 2014<br>Janssen Pharmaceuticals, Inc,<br>Titusville, New Jersey 08560</p>
<p>©Janssen Pharmaceuticals, Inc, 2014</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="section-12"></a><p></p>
<table width="100%">
<col align="left" valign="top" width="100%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">MEDICATION GUIDE<br>NIZORAL<span class="Sup">®</span><br>(ketoconazole)<br>Tablets</span></p></td></tr>
<tr><td class="Botrule Lrule Rrule" align="left">
<p class="First"><a name="what_is_the_most_important_information"></a><span class="Bold">What is the most important information I should know about NIZORAL<span class="Sup">® </span> Tablets?</span></p>
<br><p>NIZORAL<span class="Sup">® </span> Tablets is not the only medicine available to treat <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> and should only be used when other medicines are not right for you. Talk to your healthcare provider to find out if NIZORAL<span class="Sup">® </span> Tablets are right for you.</p>
<br><p><span class="Bold">NIZORAL<span class="Sup">® </span> Tablets can cause serious side effects, including:</span></p>
<br><ul class="Disc">
<li>
<span class="Bold">liver problems (hepatotoxicity). Some people who were treated with ketoconazole the active ingredient in NIZORAL<span class="Sup">® </span> Tablets, had serious liver problems that led to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or the need for a liver transplant. </span> Call your healthcare provider right away if you have any of the following symptoms: 								<ul class="Circle">
<li>loss of appetite or start losing weight (<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
<li>feel tired</li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> or <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span></li>
<li>dark urine or light colored stools</li>
<li>yellowing of your skin or the whites of your eyes</li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></li>
</ul>
</li>
<li>
<span class="Bold">changes in the electrical activity of your heart called QT prolongation. QT prolongation can cause irregular heart beats that can be life threatening. </span> This can happen when NIZORAL<span class="Sup">® </span> Tablets are taken with certain medicines, such as dofetilide, quinidine, pimozide, cisapride, methadone, disopyramide, dronedarone, and ranolazine. Talk to your healthcare provider about other medicines you are taking before you start taking NIZORAL<span class="Sup">® </span> Tablets. Tell your healthcare provider right away if you feel <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span>, lightheaded, dizzy, or feel your heart beating irregularly or fast. These may be symptoms related to QT prolongation.</li>
</ul>
</td></tr>
<tr><td class="Botrule Lrule Rrule" align="left">
<p class="First"><span class="Bold">What are NIZORAL<span class="Sup">® </span> Tablets?</span></p>
<br><ul class="Disc">
<li>NIZORAL<span class="Sup">® </span> Tablets are prescription medicine used to treat serious <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> including: <span class="product-label-link" type="condition" conceptid="433146" conceptname="Blastomycosis">blastomycosis</span>, <span class="product-label-link" type="condition" conceptid="437217" conceptname="Coccidioidomycosis">coccidioidomycosis</span>, <span class="product-label-link" type="condition" conceptid="433134" conceptname="Histoplasmosis">histoplasmosis</span>, chromomycosis, and paracoccidioidomycosis.</li>
<li>NIZORAL<span class="Sup">® </span> Tablets are not for people with fungal <span class="product-label-link" type="condition" conceptid="4080305" conceptname="Infection of nail">nail infections</span>.</li>
<li>NIZORAL<span class="Sup">® </span> Tablets have not been approved for the treatment of advanced prostate cancer or Cushing's syndrome. The safety and efficacy have not been established.</li>
<li>NIZORAL<span class="Sup">® </span> Tablets should only be used in children if prescribed by the healthcare provider who has determined that the benefits outweigh the risks.</li>
</ul>
</td></tr>
<tr><td class="Botrule Lrule Rrule" align="left">
<p class="First"><a name="who_should_not_take_nizoral_tablets"></a><span class="Bold">Who should not take NIZORAL<span class="Sup">® </span> Tablets?</span></p>
<br><ul class="Disc"><li>
<span class="Bold">Do not take NIZORAL<span class="Sup">® </span> Tablets if you:</span><ul class="Circle">
<li>have liver problems</li>
<li>take simvastatin, or lovastatin. NIZORAL<span class="Sup">® </span> Tablets when taken with these medicines may cause muscle problems.</li>
<li>take eplerenone, dihydroergotamine, ergotamine, ergometrine (ergonovine), methylergometrine (methylergonovine) or nisoldipine.</li>
<li>take triazolam, midazolam, or alprazolam. Taking NIZORAL<span class="Sup">® </span> Tablets with these medicines may make you very drowsy and make your <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> last longer.</li>
<li>are allergic to ketoconazole or any of the ingredients in NIZORAL<span class="Sup">® </span> Tablets. See the end of this Medication Guide for a complete list of ingredients in NIZORAL<span class="Sup">® </span> Tablets.</li>
</ul>
</li></ul>
</td></tr>
<tr><td class="Botrule Lrule Rrule" align="left">
<p class="First"><span class="Bold">Before you take NIZORAL<span class="Sup">® </span> Tablets, tell your healthcare provider if you:</span></p>
<br><ul class="Disc">
<li>have had an abnormal heart rhythm tracing (ECG) or anyone in your family have or have had a heart problem called "congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>".</li>
<li>have <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>.</li>
<li>are pregnant or plan to become pregnant. It is not known if NIZORAL<span class="Sup">® </span> Tablets will harm your unborn baby.</li>
<li>are breastfeeding or plan to breastfeed. NIZORAL<span class="Sup">® </span> Tablets can pass into your breast milk. You and your healthcare provider should decide if you will take NIZORAL<span class="Sup">® </span> Tablets or breastfeed. You should <span class="Bold"> NOT </span> do both.</li>
</ul>
<p>Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.</p>
<br><p>Using NIZORAL<span class="Sup">® </span> Tablets with certain other medicines may affect each other. Using NIZORAL<span class="Sup">® </span> Tablets with other medicines can cause serious side effects.</p>
</td></tr>
<tr><td class="Botrule Lrule Rrule" align="left">
<p class="First"><span class="Bold">How should I take NIZORAL<span class="Sup">® </span> Tablets?</span></p>
<br><ul>
<li>Take NIZORAL<span class="Sup">® </span> 1 time each day.</li>
<li>Do not stop taking NIZORAL<span class="Sup">® </span> Tablets without first talking to your healthcare provider.</li>
</ul>
</td></tr>
<tr><td class="Botrule Lrule Rrule" align="left">
<p class="First"><span class="Bold">What should I avoid while taking NIZORAL<span class="Sup">® </span> Tablets?</span></p>
<br><ul><li>Do not drink alcohol while taking NIZORAL<span class="Sup">® </span> Tablets.</li></ul>
</td></tr>
<tr><td class="Botrule Lrule Rrule" align="left">
<p class="First"><span class="Bold">What are the possible side effects of NIZORAL<span class="Sup">® </span> Tablets?</span></p>
<br><p><span class="Bold">NIZORAL<span class="Sup">® </span> Tablets may cause serious side effects, including:</span></p>
<br><ul class="Disc">
<li><span class="Bold">See "<a href="#what_is_the_most_important_information">What is the most important information I should know about NIZORAL® Tablets?</a>"</span></li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>. </span> <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">Adrenal insufficiency</span> is a condition in which the adrenal glands do not make enough steroid hormones. NIZORAL<span class="Sup">® </span> Tablets may cause <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> if you take a high dose. Your healthcare provider will follow you closely if you have <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> or if you are taking prednisone or other similar medicines for long periods of time. Call your healthcare provider right away if you have symptoms of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span> such as <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</li>
<li>
<span class="Bold">serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>. </span> Some people can have a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to NIZORAL<span class="Sup">® </span> Tablets. Stop taking NIZORAL<span class="Sup">® </span> Tablets and go to the nearest hospital emergency room right away if you get a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the lips or tongue, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, or have trouble breathing. These could be signs of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</li>
<li>
<span class="Bold">muscle problems. </span> Taking certain medicines with NIZORAL<span class="Sup">® </span> Tablets may cause muscle problems. See <span class="Bold"> "<a href="#who_should_not_take_nizoral_tablets">Who should not take NIZORAL® Tablets?</a>"</span>
</li>
</ul>
<p>The most common side effects of NIZORAL<span class="Sup">® </span> Tablets include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>, and <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span>.</p>
<br><p>These are not all the possible side effects of NIZORAL<span class="Sup">® </span> Tablets. For more information, ask your healthcare provider or pharmacist.</p>
<br><p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
</td></tr>
<tr><td class="Botrule Lrule Rrule" align="left">
<p class="First"><span class="Bold">How should I store NIZORAL<span class="Sup">® </span> Tablets?</span></p>
<br><ul class="Disc">
<li>Store NIZORAL<span class="Sup">® </span> Tablets at room temperature between 59°F to 77°F (15°C to 25°C).</li>
<li>Keep NIZORAL<span class="Sup">® </span> Tablets dry.</li>
</ul>
</td></tr>
<tr><td class="Botrule Lrule Rrule" align="left">
<p class="First"><span class="Bold">General information about the safe and effective use of NIZORAL<span class="Sup">® </span> Tablets.</span></p>
<br><p>Medications are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use NIZORAL<span class="Sup">® </span> Tablets for a condition for which it was not prescribed. Do not give NIZORAL<span class="Sup">® </span> Tablets to other people, even if they have the same symptoms that you have. It may harm them.</p>
<br><p>This Medication Guide summarizes the most important information about NIZORAL<span class="Sup">® </span> Tablets.</p>
<br><p>If you would like more information, talk to your healthcare provider. You can ask your pharmacist or healthcare provider for information about NIZORAL<span class="Sup">® </span> Tablets that is written for health professionals.</p>
</td></tr>
<tr class="Last"><td class="Lrule Rrule" align="left">
<p class="First"><span class="Bold">What are the ingredients in NIZORAL<span class="Sup">® </span> Tablets?</span></p>
<br><p><span class="Bold">Active ingredient: </span> ketoconazole.</p>
<br><p><span class="Bold">Inactive ingredients: </span> colloidal silicon dioxide, corn starch, lactose, magnesium stearate, microcrystalline cellulose, and povidone.</p>
<br><p>Janssen Pharmaceuticals, Inc., Titusville, New Jersey 08560, ©Janssen Pharmaceuticals, Inc. 2014 <br> Issued: 02/2014</p>
</td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<p class="First">This Medication Guide has been approved by the U.S. Food and Drug Administration</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 200 mg Bottle Label</h1>
<p class="First"><span class="Bold">100 Tablets<br>NDC 50458-220-10</span></p>
<p><span class="Bold">NIZORAL<span class="Sup">®</span></span><br>(KETOCONAZOLE<br>TABLETS)</p>
<p><span class="Bold">200 mg</span></p>
<p><span class="Bold">Each tablet contains:<br></span>Ketoconazole 200 mg</p>
<p><span class="Bold">JANSSEN</span></p>
<p>PHARMACEUTICA<br>PRODUCTS, LP</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 200 mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=090660c1-6e6d-457f-adb5-046ddfcd1465&amp;name=nizoral-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NIZORAL 		
					</strong><br><span class="contentTableReg">ketoconazole tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50458-220</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Ketoconazole</strong> (Ketoconazole) </td>
<td class="formItem">Ketoconazole</td>
<td class="formItem">200 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Starch, Corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Cellulose, Microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Povidones</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (Circular, flat bevel-edged) </td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">JANSSEN;NIZORAL</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50458-220-10</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018533</td>
<td class="formItem">06/12/1981</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Janssen Pharmaceuticals, Inc.
							(063137772)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Janssen Pharmaceutica NV, Beerse, Belgium</td>
<td class="formItem"></td>
<td class="formItem">370005019</td>
<td class="formItem">API MANUFACTURE(50458-220)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Janssen Pharmaceutica NV, Geel, Belgium</td>
<td class="formItem"></td>
<td class="formItem">374747970</td>
<td class="formItem">API MANUFACTURE(50458-220)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Noramco, Inc., Athens, USA</td>
<td class="formItem"></td>
<td class="formItem">057234486</td>
<td class="formItem">API MANUFACTURE(50458-220)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Johnson &amp; Johnson Limited (DBA Pharmaceutical Product, Analytical and Pharmaceutical Development Center), Mumbai – Maharshtra, India</td>
<td class="formItem"></td>
<td class="formItem">650447175</td>
<td class="formItem">API MANUFACTURE(50458-220)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Janssen Cilag SPA Via C. Janssen 04010 Borgo San Michele Latina, Italy</td>
<td class="formItem"></td>
<td class="formItem">542797928</td>
<td class="formItem">MANUFACTURE(50458-220), ANALYSIS(50458-220)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Janssen Ortho, LLC State Road 933, Km 0.1 Mamey Ward Gurabo, PR 00778-9629</td>
<td class="formItem"></td>
<td class="formItem">805887986</td>
<td class="formItem">PACK(50458-220)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>895d2672-26d8-4b41-9165-fae35259143d</div>
<div>Set id: 090660c1-6e6d-457f-adb5-046ddfcd1465</div>
<div>Version: 3</div>
<div>Effective Time: 20140307</div>
</div>
</div> <div class="DistributorName">Janssen Pharmaceuticals, Inc.</div></p>
</body></html>
